HC Wainwright Expects Weaker Earnings for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Investment analysts at HC Wainwright dropped their Q1 2025 earnings estimates for shares of BridgeBio Pharma in a report released on Tuesday, April 15th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.01) per share for the quarter, down from their prior forecast of ($0.83). HC Wainwright has a “Buy” rating and a $53.00 price objective on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($1.08) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($4.17) EPS and Q1 2026 earnings at ($0.85) EPS.

A number of other analysts have also recently weighed in on BBIO. Citigroup boosted their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 24th. Scotiabank upped their target price on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday, February 21st. Finally, Redburn Atlantic initiated coverage on shares of BridgeBio Pharma in a research report on Monday, March 31st. They issued a “buy” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.00.

BridgeBio Pharma Stock Performance

Shares of BBIO stock opened at $33.85 on Thursday. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $39.47. The stock’s 50 day simple moving average is $33.69 and its 200 day simple moving average is $29.95. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of -11.88 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analysts’ expectations of $4.04 million.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, Director Andrea Ellis sold 10,000 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $35.00, for a total value of $350,000.00. Following the completion of the sale, the director now directly owns 12,000 shares in the company, valued at $420,000. This represents a 45.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Brian C. Stephenson sold 68,000 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $2,467,720.00. Following the sale, the chief financial officer now directly owns 93,758 shares of the company’s stock, valued at approximately $3,402,477.82. The trade was a 42.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,694,739 shares of company stock worth $327,308,651 in the last three months. Insiders own 24.66% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors and hedge funds have recently modified their holdings of BBIO. Vanguard Group Inc. raised its stake in BridgeBio Pharma by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock valued at $413,738,000 after acquiring an additional 879,059 shares during the period. Janus Henderson Group PLC raised its holdings in BridgeBio Pharma by 1.9% in the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock valued at $134,672,000 after acquiring an additional 89,521 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of BridgeBio Pharma by 140.1% during the fourth quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock worth $115,111,000 after acquiring an additional 2,448,000 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Capital Research Global Investors grew its holdings in BridgeBio Pharma by 34.9% in the 4th quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock valued at $96,774,000 after buying an additional 912,439 shares in the last quarter. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.